Lourdes
Calvo Martínez
Complexo Hospitalario Universitario da Coruña
La Coruña, EspañaPublicaciones en colaboración con investigadores/as de Complexo Hospitalario Universitario da Coruña (35)
2024
-
Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study
Clinical and Translational Oncology, Vol. 26, Núm. 8, pp. 1896-1907
2022
-
Clinical and Sociodemographic Determinants of Adherence to World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Recommendations in Breast Cancer Survivors—Health-EpiGEICAM Study
Cancers, Vol. 14, Núm. 19
-
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study
European Journal of Cancer, Vol. 168, pp. 12-24
2021
-
Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study
European Journal of Cancer, Vol. 156, pp. 70-82
-
Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial
European Journal of Cancer, Vol. 148, pp. 382-394
2019
-
Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry)
Scientific Reports, Vol. 9, Núm. 1
2018
-
Comparing neoadjuvant nab-paclitaxel vs paclitaxel both followed by anthracycline regimens in women with ERBB2/ HER2-negative breast cancer-the evaluating treatment with neoadjuvant abraxane (ETNA) trial a randomized phase 3 clinical trial
JAMA Oncology, Vol. 4, Núm. 3, pp. 302-308
-
Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy
Clinical and Translational Oncology, Vol. 20, Núm. 12, pp. 1548-1556
2017
-
Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study
Clinical and Translational Oncology, Vol. 19, Núm. 1, pp. 91-104
-
Proteomic Analysis of the E3 Ubiquitin-Ligase Hakai Highlights a Role in Plasticity of the Cytoskeleton Dynamics and in the Proteasome System
Journal of Proteome Research, Vol. 16, Núm. 8, pp. 2773-2788
2016
-
Diagnostic accuracy of MRI to evaluate tumour response and residual tumour size after neoadjuvant chemotherapy in breast cancer patients
Radiology and Oncology, Vol. 50, Núm. 1, pp. 73-79
-
Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Results from the Spanish Breast Cancer Group/2009-02 study
European Journal of Cancer, Vol. 58, pp. 122-129
2015
-
Defining breast cancer intrinsic subtypes by quantitative receptor expression
Oncologist, Vol. 20, Núm. 5, pp. 474-482
2014
-
Predicting response and survival in chemotherapy-treated triple-negative breast cancer
British Journal of Cancer, Vol. 111, Núm. 8, pp. 1532-1541
-
Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: Results from the GEICAM/2006-14 trial
British Journal of Cancer, Vol. 110, Núm. 5, pp. 1139-1147
2012
-
A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study
Breast Cancer Research and Treatment, Vol. 136, Núm. 2, pp. 487-493
-
Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: Results from the GEICAM/2006-03, a multicenter, randomized, phase-II study
Annals of Oncology, Vol. 23, Núm. 12, pp. 3069-3074
2011
-
A dose-dense schedule of docetaxel followed by doxorubicin and cyclophosphamide as neoadjuvant treatment for breast cancer: Results from a phase II study
Clinical and Translational Oncology, Vol. 13, Núm. 9, pp. 686-691
-
Phase I/II study of biweekly vinorelbine and oxaliplatin as first-line treatment in patients with metastatic breast cancer
Anti-Cancer Drugs, Vol. 22, Núm. 3, pp. 283-289
-
Phase II clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neoadjuvant treatment in stages II and IIIA HER2-overexpressing breast cancer patients. GEICAM 2003-03 study
Annals of Oncology, Vol. 22, Núm. 1, pp. 74-79